Precision Medicines
OverviewSuggest Edit
Precision Medicines is a clinical-stage biotechnology company. It focuses on in-licensing drug candidates for the treatment of various forms of cancer and then seeks to further develop these drug candidates for commercial use.
| Type | Private | |
| HQ | Macclesfield, GB | Map |
| Website | precimeds.com |
Recent NewsAll News
- Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement with Huadong to Advance Hydroxyl Dendrimer-Based Precision Medicines
- Creyon Bio Launches to Engineer Safe, Effective Precision Medicines on Demand for All Patients
- RNA Transcriptomics Market Size to Reach USD 12.46 Billion in 2028 | Increasing Demand for Precision Medicines And Growing Investment are Major Factors Fueling Industry Growth, says Emergen Research
Latest Updates
| Employees (est.) (Feb 2020) | 4 | |
| Cybersecurity rating | B | More |
Key People/Management at Precision Medicines
Ansar Jawaid
Founder and Chief Executive Officer
Ulf Jungnelius
Chief Medical Officer
Precision Medicines Online and Social Media Presence
Precision Medicines's Trends
Precision Medicines News and Updates
April 27, 2022
Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement with Huadong to Advance Hydroxyl Dendrimer-Based Precision Medicines
– Series B Financing led by Huadong Medicine Investment Holding Co., Ltd, with participation from Natural Capital Investment Fund, Plum Alley Investments and Tribe Capital –
March 08, 2022
Creyon Bio Launches to Engineer Safe, Effective Precision Medicines on Demand for All Patients
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., March 8, 2022 /PRNewswire/ -- Creyon Bio, Inc. ("Creyon Bio"), a drug development company engineering RNA-based medicines and their components (oligonucleotide-based medicines or OBMs) with predictable safety and efficacy profiles, launched...
April 12, 2021
RNA Transcriptomics Market Size to Reach USD 12.46 Billion in 2028 | Increasing Demand for Precision Medicines And Growing Investment are Major Factors Fueling Industry Growth, says Emergen Research
Key players operating in the RNA Transcriptomics market are Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Merck KGaA, Agilent Technologies, Inc., Illumina, Inc., GenXPro GmbH, Fluidigm Corporation, CD Genomics, Sequentia Biotech SL, and Acobiom. Key players operating in the RNA Transcr…
Precision Medicines Frequently Asked Questions
Who are Precision Medicines key executives?
Precision Medicines's key executives are Ansar Jawaid and Ulf Jungnelius.
How many employees does Precision Medicines have?
Precision Medicines has 4 employees.
Who are Precision Medicines competitors?
Competitors of Precision Medicines include ImmunSYS, NOXXON Pharma and ASLAN Pharmaceuticals.
Where are Precision Medicines offices?
Precision Medicines has an office in Macclesfield.
How many offices does Precision Medicines have?
Precision Medicines has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies